Filing Flows

Filing Flows › Companies › Evofem Biosciences › Cash flow

Evofem Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.1M in Q2 2026 · −$477K over twelve months

Operating cash flow−$3.1M
Free cash flow−$3.1M
Cash conversion cycle-1738 days

Analysis

In Q2 2026, Evofem Biosciences generated −$3.1M of operating cash flow. That is $221K less than in Q2 2025 (−$2.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$472K; the largest uses were operating cash flow ($472K), other financing ($12K), capital spending ($5K); besides operations, cash came from net borrowing (+) / repaid (−) ($26K); the cash balance fell by $463K.

Operating cash flow was −$3.1M against net income of −$11.0M. The largest differences: receivables −$1.9M, employee-related liabilities +$682K, accrued liabilities +$600K.

Its cash conversion cycle was -1738 days (receivables 53 + inventory 360 − payables 2151): suppliers fund its working capital.

Free cash flow

Evofem Biosciences: free cash flow by quarterEvofem Biosciences: free cash flow by quarter−$459KQ3 2024−$2.4MQ4 2024$560KQ1 2025−$2.9MQ2 2025$336KQ3 2025$28KQ4 2025$2.3MQ1 2026−$3.1MQ2 2026
Operating cash flow less capital spending.
Evofem Biosciences: operating cash flow against capital spendingEvofem Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$459K$0Q3 2024−$2.4M$0Q4 2024$560K$0Q1 2025−$2.9M$0Q2 2025$336K$0Q3 2025$31K$3KQ4 2025$2.3M$2KQ1 2026−$3.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$3.1M, Capital spending $0.

Capital allocation, year by year

Evofem Biosciences: where the cash came from (up) and went (down), by fiscal yearEvofem Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$147MFY2021: Shares issued $10.0MFY2021: Asset sales $250KFY2021: Capital spending −$2.9M$10.2MFY2021FY2022: Operating cash flow −$70.4MFY2022: Net borrowing $5.6MFY2022: Capital spending −$341KFY2022: Buybacks −$18K$5.6MFY2022FY2023: Operating cash flow −$9.0MFY2023: Net borrowing $5.6MFY2023: Capital spending −$4K$5.6MFY2023FY2024: Operating cash flow −$3.9MFY2024: Shares issued $5.0MFY2024: Capital spending −$14KFY2024: Acquisitions −$555K$5.0MFY2024FY2025: Operating cash flow −$2.0MFY2025: Net borrowing −$522KFY2025: Capital spending −$5KFY2025
Over these 5 years operating cash flow totalled −$232M; the largest uses were operating cash flow ($232M) and capital spending ($3.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$285K
Debt$362K
Net debt$77K
Cash runway7 months

Evofem Biosciences is burning cash: its operations consume cash, a free cash flow of −$477K a year at the current rate against $285K of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Evofem Biosciences: sources (+) and uses (−) of cash, Q2 2026Evofem Biosciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$3.1MCash drawn (+) / kept (−)$2.1MOther financing$1.1MNet borrowing (+) / repaid (−)−$22K
Evofem Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Evofem Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$472KCash drawn (+) / kept (−)$463KNet borrowing (+) / repaid (−)$26KOther financing−$12KCapital spending−$5K

From profit to cash

Evofem Biosciences: net income to operating cash flow, Q2 2026Evofem Biosciences: net income to operating cash flow, Q2 2026Net income−$11.0MDepreciation & amortization$18KReceivables−$1.9MInventory−$265KPayables$29KAccrued liabilities$600KEmployee-related liabilities$682KPrepaid and other assets$83KOperating cash flow−$3.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026533602151-1738
Q1 20266533312761-1777
Q4 20258150440-308
Q3 2025871821216-946
Q2 2025572511417-1109
Q1 20255854733378-2319
Q4 202499921005-814
Q3 20241021341741-1505

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$3.1M——−$22K—$2.1M−$3.1M
Q1 2026$2.3M−$2K—−$498K—−$1.8M$2.3M
Q4 2025$31K−$3K—−$278K—$262K$28K
Q3 2025$336K——−$244K—−$92K$336K
Q2 2025−$2.9M——−$248K—$361K−$2.9M
Q1 2025$560K—−$57K−$135K—−$368K$560K
Q4 2024−$2.4M—−$46K−$367K$3.7M−$19K−$2.4M
Q3 2024−$459K————−$30K−$459K

Evofem Biosciences: income statement and cash flow

Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%. The chart follows the revenue to costs, profit and cash.

Evofem Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.